

2008年傑出系友得獎人—洪昭雄校友

Dr. Jau-Shyong Hong is the Head of the Neuropharmacology Section of the Intramural Research Program, National Institute of Environmental Health Sciences, National Institutes of Health (NIH), Research Triangle Park, North Carolina. He received his B.S. degree from the National Taiwan University (第十屆) and Ph.D. in pharmacology at the University of Kansas. He did his postdoctoral training at the National Institute of Mental Health, NIH.



Dr. Hong's research has focused on the role of inflammation in the pathogenesis of neurodegenerative diseases, such as Parkinson's disease. His laboratory was the first to demonstrate that immune cells in brain, microglia, are critical in the pathogenesis of this degenerative disease. This finding leads to a novel therapy using newly development anti-inflammatory drug for Parkinson's patients. Based these findings, NIH filed a patent for further developing anti-inflammatory therapy. Recently, using the newly developed drugs, several clinical trials have shown beneficial effects on patients suffered from inflammation-related diseases, including neurodegenerative diseases, mental disorders and neuropathic pains.

Dr. Hong holds Adjunct professorship at Duke University, University of North Carolina. He is the recipient of NIH Outstanding Research Award and Mentor of the Year Award.

2008年傑出系友得獎人—梁啟銘校友

梁啟銘博士，本系第14屆系友，西元1970年畢業後，先在台大化學研究所取得碩士，並在1977年於University of Arkansas for Medical Sciences 拿到博士學位，隨即到美國國家衛生研究院(National Institutes of Health)研究，並在世界知名生技公司Biogen及美國藥物食品檢驗局(Food and Drug Administration)擔任主管，他熱心服務，關懷母系，在1978年即協助許瀛旭系友籌設北美系友會，增進系友對本系之凝聚力。在1997年回國，於中央研究院生化所當研究員，兼公共事務組主任及育成中心執行長，在生化、免疫、癌症方面悉心研究，發表了七十多篇學術論文，並利用其二十多年之經驗，負責推動科技移轉，十年來頗有建樹，尤其在生技醫藥方面。現任國家衛生研究院特聘研究員兼主秘(Secretary General, NHRI)，並是中央研究院院長資深顧問(Senior Advisor, President Office, Academia Sinica)，對我國科技移轉制度的建立



與生技醫藥之發展貢獻良多，深獲推崇。他待人以誠，除了擔任中華景康藥學基金會董事，亦是台灣技術經理人協會常務理事、亞太智慧財產權發展基金會董事、台灣生物化學及分子生物學會理事、生物產業發展協會董事及國家生技醫療產業策進會理事。梁校友在產、官、學、研各方面都有很傑出之成就，而其熱心公益、無私奉獻的精神更足為楷模。

2008年傑出校友得獎人—許中強

Dr. Larry Chung-Chiang Hsu is the President and Chief Executive Officer of Impax Laboratories, Inc., based in the San Francisco Bay Area in California, U.S.A. He received his B.S. degree from National Taiwan University in Taipei (第15屆) and Ph.D. degree from the Pharmaceutics from University of Michigan, U.S.A.

Dr. Hsu co-founded Impax Pharmaceuticals, Inc. in 1994. He was instrumental in taking Impax public in December 1999 through a reverse acquisition of Global Pharmaceuticals and the renaming of the company as Impax Laboratories, Inc. Impax Laboratories is a technology-based specialty pharmaceutical company utilizing its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics and the development of branded products. In the generic pharmaceuticals market, Impax is primarily focusing its efforts on selected controlled-release generic versions of brand name pharmaceuticals. Impax is also developing other generic pharmaceuticals that it believes present one or more competitive barriers to entry, such as difficulty sourcing raw materials, complex formulation or development characteristics, or special handling requirements. In the brand name pharmaceuticals market, Impax is developing products for the treatment of central nervous system disorders. Impax's initial brand name product portfolio consists of development-stage projects that are applying their formulation and development expertise to develop differentiated, modified, or controlled-release versions of currently marketed drug substances. Dr. Hsu intends to expand Impax's brand name products portfolio primarily through internal development and, in addition, through licensing and acquisition.

Prior to co-founding Impax, Dr. Hsu had served in various influential executive positions from 1980 to 1995 at Abbott Laboratories. He was the Director of Product Development in charge of worldwide product development, process engineering, and clinical lot manufacturing and production technical support of all dosage forms.

Dr. Hsu has many publications including book chapters in new drug discovery and drug delivery technology areas. He also is the principal inventor of many patents.

